Actym Therapeutics, Inc.

We are excited to announce the appointments of Mary J. Janatpour, PhD, as Chief Scientific Officer and Shouryadeep Srivastava, MD, PhD, as Senior Vice President of Clinical Development. Drs. Janatpour and Srivastava bring extensive therapeutic product discovery and development expertise as Actym continues the clinical advancement of its lead program and expands its portfolio of drug candidates.   In May, Actym announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to start a Phase 1 clinical trial of lead drug candidate ACTM-838. The Phase 1 trial will assess safety, tolerability, and efficacy signals of ACTM-838 as a single agent and will be conducted at clinical sites in the U.S. and Australia. Read the full announcement here: https://lnkd.in/d7GJhPc6 #CancerResearch #ClinicalDevelopment #ACTM838

We are excited to announce the clearance of Actym’s investigational new drug (IND) application by the U.S. FDA for our flagship drug candidate, ACTM-838, to initiate clinical studies in patients with advanced solid tumors. ACTM-838 is the first clinical candidate developed using our proprietary STACT™ biological platform that targets the tumor microenvironment (TME). Our engineered new drug modality harnesses the power of a genetically modified bacterial vehicle to safely introduce therapeutic payload combinations to activate the immune response in the TME.  Specifically, ACTM-838 is designed to be systemically-administered and selectively accumulate in the TME to locally express two potent payloads, engineered versions of IL-15/IL-15Ra and STING, to stimulate both innate and adaptive anti-tumor immunity. The upcoming Phase 1 trial will assess safety, tolerability, and efficacy signals of ACTM-838 as a single agent and will be conducted at clinical sites in the U.S. and Australia. Read the full announcement here: https://lnkd.in/dMkjFqM3 #CancerResearch #ClinicalDevelopment #ACTM838 

We would like to welcome Thomas Smart as the new Chief Executive Officer of Actym Therapeutics! With 25 years of senior management experience in the biopharmaceutical industry, Tom is poised to lead Actym into the next phase of growth including our upcoming transition into being a clinical-stage company in the second quarter of 2024. Actym is revolutionizing cancer treatment with our innovative STACT approach, which leverages a genetically modified bacteria vehicle, systemically administered, that achieves tissue-specific delivery of large nucleic acid payloads. Under Tom’s leadership, Actym will start the clinical evaluation of our lead candidate, ACTM-838, and continue to expand our pipeline with additional candidates from Actym’s modular platform. Learn more about Tom and the Actym team here: https://lnkd.in/dhRrjB7N #NewHire #ClinicalDevelopment #ACTM838

AACR Poster Presentation Meet us in San Diego! Our Senior Director of Immunology and Translational Sciences, Dr. Akshata Udyavar and our Associate Director of Translational Sciences, Dr. William Lu will be on site and presenting a poster at the @American Association for Cancer Research Annual Meeting 2024. Don’t miss the presentation on how our clinical-stage asset ACTM-838 is altering the tumor microenvironment and delivering potent anti-tumor activity in vivo. Abstract Number: 736 Date & Time: April 7, 2024, 1:30 – 5:00 PM Poster Title: "A systemically delivered, clinically-ready, attenuated Salmonella Typhimurium strain ACTM-838 alters the tumor microenvironment and provides durable anti-tumor activity in vivo" #AACR2024 #ACTM838

A big welcome to Shouryadeep “Deep” Srivastava M.D., Ph.D., as Actym Therapeutics' new SVP of Clinical Development! Dr. Shouryadeep Srivastava brings over 13 years of clinical research experience in the biotechnology and pharmaceutical industries, specializing in both early and late-stage drug development. His expertise will be instrumental in advancing our lead candidate, ACTM-838, through clinical trials, with our Phase 1 trial expected to start later this year. #NewHire #ClinicalDevelopment #ACTM838 Learn more about the Actym team here: https://lnkd.in/dhRrjB7N

Will you be at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting? Join us for our poster presentation on Saturday, November 4, from 11:55 AM – 1:25 PM and 7:00 PM – 8:30 PM (PST). Our Senior Director of Immunology and Translational Sciences, Dr. Akshata Udyavar will present preclinical data of our lead asset, ACTM-838, in a poster presentation, “PK/PD biomarker analysis to assess tumor-specific enrichment and payload delivery of ACTM-838, a microbial-based immunotherapy.” The presentation will feature data examining the tumor-specific enrichment and payload delivery of ACTM-838 in multiple tumor models. We look forward to seeing you there! Learn more about the presentation here: https://bit.ly/3QJjgCr

If you are at this year's Society for Immunotherapy of Cancer (SITC) Annual Meeting, don’t miss the opportunity to stop by our poster presentation led by Dr. Akshata Udyavar, Senior Director of Immunology and Translational Sciences, on November 4th. Our poster presentation will display important preclinical data of ACTM-838, our lead asset, focusing on tumor-specific enrichment and payload delivery. See you there!   #SITC2023 #CancerResearch #Immunotherapy   Learn more about the presentation here: https://bit.ly/3QJjgCr

A warm, official welcome to Steve Vicik who has joined the Actym team as Chief Technical Officer! Steve brings 25+ years of experience in #pharmaceutical process and product development, manufacturing operations, as well as supply chain design and distribution for large and small molecule drugs. He will lead and execute our technology strategy and advance our proprietary platform, S. Typhimurium-Attenuated Cancer Therapy (STACT), which represents a novel approach to achieving comprehensive immunological reprogramming of the #tumor microenvironment.   Learn more about his appointment here: https://lnkd.in/dFzmGHwJ

Thank you, Ron Leuty and San Francisco Business Times, for featuring Actym and our #SeriesA financing extension announcement. A big shoutout to the Actym team for their hard work, especially as we move into clinical testing – it wouldn’t be possible without each one of our team members! To learn how this #investment will support advancing our lead candidate ACTM-838, read the full article here: https://lnkd.in/dq7XwH5j

We've successfully added a $25.5 million extension to our #SeriesA, bringing the round total to $59.5 million. This extension will support our Phase 1 #clinicaltrial, aiming to achieve proof of mechanism of our lead candidate, ACTM-838, demonstrating it’s ability to selectively enrich in #tumors, deliver payload combinations there, and positively re-activate the immuno-compromised #TME. In addition, the trial is designed to assess the dose selection, safety, efficacy and pharmacokinetics of ACTM-838. A special acknowledgment to Boehringer Ingelheim Venture Fund and Illumina Ventures for co-leading this extension, and a warm welcome to GKCC LLC, our newest investor. Gratitude to Panacea Venture and JLo Ventures, our current shareholders which also participated in the round.   Discover more: https://lnkd.in/emCPExVS